腺嘌呤核苷酸调控2型糖尿病小鼠肝脏PTP1B活性
该研究探讨腺嘌呤核苷酸在2型糖尿病中的代谢调控作用。小鼠模型和2型糖尿病患者血浆5'-AMP升高,5'-AMP诱导的代谢物谱与db/db小鼠相似,ATP与二甲双胍通过改变细胞pH反向调节肝脏PTP1B活性,提示腺嘌呤核苷酸是潜在治疗靶点。
要点
- 2型糖尿病小鼠模型及患者血浆5'-AMP水平均升高。
- 5'-AMP升高是肥胖小鼠发生高血糖所必需的。
- ATP与二甲双胍通过改变肝细胞pH反向调节PTP1B活性。
核心结论
- 腺嘌呤核苷酸在调控高血糖中起重要作用,是肥胖和2型糖尿病的潜在治疗靶点。
研究设计与样本
- 研究采用多种2型糖尿病小鼠模型,通过HPLC检测腺嘌呤核苷酸及其代谢物,并进行1H NMR代谢组学分析、酶动力学和蛋白结合实验。
- 体外使用人重组PTP1B和AML12肝细胞系,并分析了2型糖尿病参与者的血浆5'-AMP水平。
主要发现
- db/db小鼠血浆5'-AMP为13.9 ± 2.3 μmol/l,高于瘦鼠的3.7 ± 0.9 μmol/l(p < 0.01)。
- ob/ob小鼠血浆5'-AMP为9.1 ± 2.0 μmol/l,高于瘦鼠的3.9 ± 1.2 μmol/l(p < 0.01)。
- 高脂饮食/链脲佐菌素诱导小鼠血浆5'-AMP为6.6 ± 1.5 μmol/l,高于野生型的4.1 ± 0.9 μmol/l(p < 0.05)。
- 2型糖尿病患者血浆5'-AMP为45.2 ± 22.7 nmol/l,高于对照的3.1 ± 1.9 nmol/l(p < 0.01)。
- 5'-AMP处理野生型小鼠的代谢物谱与db/db糖尿病小鼠相似,尤其表现为大量ATP及其代谢物积累。
临床怎么用
- 二甲双胍可减轻5'-AMP诱导的野生型小鼠和db/db小鼠的高血糖严重程度。
- 二甲双胍降低高血糖小鼠肝脏ATP积累但不影响其代谢物。
- ATP和二甲双胍通过相互改变肝细胞pH稳态,反向调节肝脏PTP1B活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Plasma 5'-AMP (pAMP) is elevated in mouse models of type 2 diabetes. However, the metabolic regulatory role of adenine nucleotides in type 2 diabetes remains unclear. METHODS: Adenine nucleotides and their metabolites in plasma and liver were examined by HPLC. 1H NMR-based metabolomics analysis was performed to explore the changes of metabolites in mouse models of type 2 diabetes. Na+/K+ ATPase and Na+/H+ exchanger activity were measured in response to adenine nucleotide metabolites. Human recombinant protein tyrosine phosphatase 1B (PTP1B) was used for enzyme kinetic assays. Protein binding assays were performed with microscale thermophoresis. The intracellular pH of hepatocyte AML12 cell lines was measured using the BCECF-AM method. We also analysed pAMP levels in participants with type 2 diabetes. RESULTS: Elevation of pAMP was a universal phenomenon in all mouse models of type 2 diabetes including db/db vs lean mice (13.9 ± 2.3 μmol/l vs 3.7 ± 0.9 μmol/l; p < 0.01), ob/ob vs lean mice (9.1 ± 2.0 μmol/l vs 3.9 ± 1.2 μmol/l; p < 0.01) and high-fat diet/streptozotocin-induced vs wild-type mice (6.6 ± 1.5 μmol/l vs 4.1 ± 0.9 μmol/l; p < 0.05); this elevation was required for the occurrence of hyperglycaemia in obese mice. 1H NMR-based metabolomics study following HPLC analysis revealed that the metabolite profile in wild-type mice treated with 5'-AMP was similar to that in db/db diabetic mice, especially the accumulation of a large quantity of ATP and its metabolites. The glucose-lowering drug metformin reduced the severity of hyperglycaemia both in 5'-AMP-induced wild-type mice and db/db mice. Metformin decreased the accumulation of liver ATP but not its metabolites in these hyperglycaemic mice. ATP and metformin reciprocally change cellular pH homeostasis in liver, causing opposite shifts in liver activity of PTP1B, a key negative regulator of insulin signalling. Furthermore, pAMP levels were also elevated in individuals with type 2 diabetes (45.2 ± 22.7 nmol/l vs 3.1 ± 1.9 nmol/l; p < 0.01). CONCLUSIONS/INTERPRETATION: These results reveal an emerging role for adenine nucleotide in the regulation of hyperglycaemia and provide a potential therapeutic target in obesity and type 2 diabetes.
引用
- Yang X, Zhao Y, Sun Q, et al. Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes. Diabetologia. 2019. PMID: 31410531. doi:10.1007/s00125-019-04971-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。